查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949552

基因組癌症檢測市場－全球產業規模、佔有率、趨勢、機會及預測（依檢測類型、技術、最終用戶、地區及競爭格局分類，2021-2031年）

Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因組癌症檢測市場預計將從 2025 年的 144.8 億美元成長到 2031 年的 263.7 億美元，複合年成長率為 10.51%。

該市場由分析腫瘤DNA內基因突變以指南個人化癌症治療的診斷解決方案組成。推動該領域發展的關鍵因素是精準醫療的廣泛接受度以及癌症發生率的顯著上升，而這需要精準的分子分析。根據美國癌症協會的數據，預計到2024年美國將新增2,001,140例癌症病例，凸顯了日益沉重的疾病負擔，也推動了對先進診斷干預和標靶治療的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 144.8億美元
市場規模：2031年 263.7億美元
複合年成長率：2026-2031年 10.51%
成長最快的細分市場 液態生物檢體
最大的市場 北美洲

技術的應用透過實現多種突變的同時檢測，簡化治療方法決策流程，進一步推動了市場成長。醫療服務提供者越來越重視這些詳細的資訊，以透過個人化護理方案提高患者生存率。然而，該行業面臨著許多障礙，例如報銷機制的不一致和高昂的實施成本，這些都持續阻礙醫療服務的公平獲取，並限制了對成本敏感的醫療體系的市場擴張。

市場促進因素

將人工智慧 (AI) 應用於基因組分析，能夠直接處理與次世代定序相關的複雜數據，從而顯著提升腫瘤分析的速度和準確性。借助機器學習演算法，實驗室可以更有效地解讀海量基因組資料集，並識別傳統方法可能遺漏的罕見突變和治療標靶。這種技術綜效正在推動顯著的商業性成長，助力醫療服務提供者提升診斷能力。例如，Tempus AI 在 2025 年第三季報告（2025 年 11 月）中公佈，收入淨額3.342 億美元（年成長 85%），這主要歸功於其人工智慧驅動的數據和基因組學服務，凸顯了計算能力在精準腫瘤學發展中的關鍵作用。

同時，非侵入性液態生物檢體日益受到青睞，為患者提供了比組織取樣更便捷的選擇，並擴大了市場進入。這些血液檢測能夠持續監測治療反應並早期發現復發，且無需承擔手術切片檢查的風險，這項變化也反映在檢測量的成長上。根據 Guardant Health 發布的《2025 年第三季財務報告》（2025 年 10 月），腫瘤檢測量年增 40%，達到約 74,000 例。液體活體組織切片的普及對於應對全球醫療保健需求至關重要。正如 ASCO Post（2025 年 10 月號）引用《癌症圖譜》（第四版）預測的那樣，2022 年至 2050 年間，全球癌症負擔預計將成長約 74%，每年新增病例將達到 3300 萬例，因此亟需像液態生物檢體這樣可擴展的解決方案。

市場挑戰

高昂的實施成本和不一致的報銷政策是限制全球基因組癌症檢測市場成長的主要阻礙因素。保險公司通常將全面性的基因組分析歸類為實驗性或非必要醫療項目，導致拒保，給患者帶來沉重的經濟負擔。當報銷途徑有限或不明確時，臨床檢查室無法收回投入這些檢測的大量資金，而醫生也不願為患者開立他們負擔不起的診斷檢測。這種經濟上的不匹配減少了檢測數量，限制了市場滲透率，尤其是在醫療基礎設施成本控制較嚴格的地區。

此外，行政障礙會延誤或阻礙患者獲得治療，進一步加劇經濟障礙的影響。根據美國醫學會 (AMA) 預測，到 2024 年，78% 的醫生表示，事先核准政策經常導致患者放棄建議的檢查或治療。如此高的檢查放棄率表明，限制性的支付方政策會直接降低市場收入。因此，由於缺乏持續的保險覆蓋，基因組檢測的應用仍然主要局限於資金雄厚的學術機構，阻礙了永續市場成長所需的廣泛普及。

市場趨勢

次世代定序向院內臨床檢查室的去中心化正在從根本上重塑市場格局，使醫院能夠在院內進行基因組檢測。過去複雜的分子譜分析通常外包給參考實驗室（往往導致延誤），但如今，獲得監管機構核准的試劑盒和易於使用的台式測序儀的出現，使得本地醫療機構能夠在院內進行全面的分子譜分析，並即時獲取數據。這種技術在該地區日益普及，顯著推動了臨床定序試劑的消耗。 Illumina公司在其2024會計年度第三季財報（2024年11月發布）中指出，定序耗材收入達到7.41億美元，年增7%，這主要得益於該公司平台在醫院環境中的臨床應用日益廣泛。

同時，伴隨診斷（CDx）合作的拓展正在加強藥物研發與診斷檢測之間的關聯。藥物研發公司擴大從早期臨床試驗階段就與診斷公司合作，共同開發檢驗的檢測方法，確保新型標靶治療能夠與即用型生物標記檢測相結合。這種合作模式能夠加速患者識別，並最大限度地即時新藥的臨床應用率。其商業性影響顯著，凱傑公司發布的「2024年第三季財務業績」（2024年11月）也印證了這一點。經外匯調整後，公司診斷解決方案部門的營收成長了10%，這一業績成長顯然得益於伴隨診斷合作夥伴關係的拓展。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因組癌症檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依檢測類型（基因組分析檢測、液態生物檢體檢測、伴隨診斷檢測、藥物基因體學檢測、遺傳性癌症檢測、其他）
    • 依技術分類（次世代定序（NGS）、聚合酵素鏈鎖反應（PCR）、螢光原位雜合反應（FISH）、免疫組織化學（IHC）、其他）
    • 依最終使用者（醫院、診斷檢查室、學術研究機構、癌症中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美基因組癌症檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲基因組癌症檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區基因組癌症檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲基因組癌症檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲基因組癌症檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因組癌症檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Merck KGaA
  • Abbott Laboratories Inc.
  • Novogene Co., Ltd.
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24306

The Global Genomic Cancer Testing Market is projected to expand from USD 14.48 Billion in 2025 to USD 26.37 Billion by 2031, reflecting a CAGR of 10.51%. This market consists of diagnostic solutions designed to examine genetic mutations in tumor DNA, thereby guiding personalized oncology treatments. A primary driver for this sector is the broad acceptance of precision medicine combined with a critical increase in cancer incidence rates that necessitate accurate molecular profiling. Data from the American Cancer Society indicates that 2,001,140 new cancer cases are expected in the United States in 2024, highlighting the escalating disease burden that fuels the need for advanced diagnostic interventions and targeted therapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 14.48 Billion
Market Size 2031USD 26.37 Billion
CAGR 2026-203110.51%
Fastest Growing SegmentLiquid Biopsy
Largest MarketNorth America

Technological adoption further bolsters market growth by facilitating the simultaneous detection of multiple mutations, which streamlines the decision-making process for therapeutics. Providers are increasingly prioritizing these detailed insights to improve patient survival rates through customized care plans. However, the industry encounters a major hurdle regarding inconsistent reimbursement frameworks and high implementation expenses, which continue to obstruct equitable access and restrict market expansion across healthcare systems that are sensitive to costs.

Market Driver

The incorporation of Artificial Intelligence into Genomic Analysis is transforming the speed and precision of tumor profiling by directly managing the data complexity associated with next-generation sequencing. By utilizing machine learning algorithms, laboratories can interpret massive genomic datasets more effectively, pinpointing rare mutations and therapeutic targets that conventional methods might overlook. This technological synergy drives significant commercial growth as providers enhance their diagnostic capabilities; for instance, Tempus AI reported in its 'Q3 2025 Quarterly Report' (November 2025) a net revenue of $334.2 million, an 85% year-over-year increase largely attributed to its AI-enabled data and genomics services, underscoring the vital role of computational power in scaling precision oncology.

Simultaneously, the growing preference for Non-Invasive Liquid Biopsy is widening market access by providing a patient-friendly alternative to tissue sampling. These blood-based tests enable continuous monitoring of treatment responses and early recurrence detection without the risks linked to surgical biopsies, a shift reflected in rising test volumes. Guardant Health's 'Third Quarter 2025 Financial Results' (October 2025) noted a 40% year-over-year increase in oncology test volume to approximately 74,000 tests. This adoption is crucial for managing global healthcare demand, as The ASCO Post (October 2025), citing 'The Cancer Atlas, 4th Edition', projects the global cancer burden will rise by roughly 74% from 2022 to 2050 to 33 million new annual cases, necessitating scalable solutions like liquid biopsy.

Market Challenge

High implementation costs and inconsistent reimbursement policies constitute a primary restraint on the growth of the Global Genomic Cancer Testing Market. Insurers often categorize comprehensive genomic profiling as experimental or medically unnecessary, leading to coverage denials that impose a severe financial strain on patients. When reimbursement pathways are restrictive or unclear, clinical laboratories struggle to recover the significant capital invested in these tests, and physicians are deterred from ordering diagnostics that patients cannot afford. This economic misalignment reduces the volume of processed tests and limits market penetration, especially in regions with cost-conscious healthcare infrastructures.

Administrative hurdles further amplify the impact of these financial barriers by delaying or blocking access to care. According to the American Medical Association, 78% of physicians in 2024 reported that prior authorization policies frequently resulted in patients abandoning recommended tests or treatments. This high rate of test abandonment illustrates how restrictive payer policies directly diminish market revenue. Consequently, without consistent coverage, the adoption of genomic testing remains largely confined to well-funded academic centers, hindering the broader expansion required for sustained market growth.

Market Trends

The decentralization of Next-Generation Sequencing to in-house clinical labs is fundamentally reshaping the market by allowing hospitals to perform genomic testing on-site. While complex molecular profiling was historically outsourced to reference laboratories-often causing delays-the availability of regulatory-approved kitted solutions and user-friendly desktop sequencers now empowers local institutions to conduct comprehensive profiling internally for immediate data access. This shift toward local adoption is driving significant consumption of clinical sequencing reagents; Illumina's 'Third Quarter 2024 Financial Results' (November 2024) reported a 7% year-over-year increase in sequencing consumables revenue to $741 million, attributed to the rising clinical utilization of their platforms in hospital settings.

In parallel, the proliferation of Companion Diagnostic (CDx) collaborations is strengthening the connection between pharmaceutical development and diagnostic testing. Drug developers are increasingly partnering with diagnostic firms during early clinical trials to co-develop validated assays, ensuring that novel targeted therapies are launched with ready-to-use biomarker tests. This collaborative model accelerates patient identification and maximizes the immediate clinical uptake of new drugs. The commercial impact is significant, as evidenced by Qiagen's 'Q3 2024 Financial Results' (November 2024), where sales in the Diagnostic Solutions group rose 10% at constant exchange rates, a performance explicitly driven by the expansion of partnerships for companion diagnostic co-development.

Key Market Players

  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Merck KGaA
  • Abbott Laboratories Inc.
  • Novogene Co., Ltd.
  • Guardant Health, Inc.
  • Personal Genome Diagnostics Inc.
  • Thermo Fisher Scientific Inc.
  • NeoGenomics Laboratories, Inc.

Report Scope

In this report, the Global Genomic Cancer Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Cancer Testing Market, By Test Type

  • Genomic Profiling Tests
  • Liquid Biopsy Tests
  • Companion Diagnostic Tests
  • Pharmacogenomic Tests
  • Hereditary Cancer Tests
  • Others

Genomic Cancer Testing Market, By Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others

Genomic Cancer Testing Market, By End User

  • Hospitals
  • Diagnostic Laboratories
  • Academic and Research Institutions
  • Cancer Centers
  • Others

Genomic Cancer Testing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomic Cancer Testing Market.

Available Customizations:

Global Genomic Cancer Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Cancer Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, Others)
    • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 5.2.3. By End User (Hospitals, Diagnostic Laboratories, Academic and Research Institutions, Cancer Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Genomic Cancer Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Technology
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genomic Cancer Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Genomic Cancer Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Genomic Cancer Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End User

7. Europe Genomic Cancer Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Technology
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genomic Cancer Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End User
    • 7.3.2. France Genomic Cancer Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Genomic Cancer Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Genomic Cancer Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Genomic Cancer Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End User

8. Asia Pacific Genomic Cancer Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Technology
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genomic Cancer Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End User
    • 8.3.2. India Genomic Cancer Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Genomic Cancer Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Genomic Cancer Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Genomic Cancer Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End User

9. Middle East & Africa Genomic Cancer Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Technology
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genomic Cancer Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Genomic Cancer Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Genomic Cancer Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End User

10. South America Genomic Cancer Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Technology
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genomic Cancer Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Genomic Cancer Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Genomic Cancer Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genomic Cancer Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd
  • 15.3. QIAGEN NV
  • 15.4. Merck KGaA
  • 15.5. Abbott Laboratories Inc.
  • 15.6. Novogene Co., Ltd.
  • 15.7. Guardant Health, Inc.
  • 15.8. Personal Genome Diagnostics Inc.
  • 15.9. Thermo Fisher Scientific Inc.
  • 15.10. NeoGenomics Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer